Asphaug L, Akslen LA, Blix ES, Boge B, Borgen EF, Brekke MB, Falk RS, Geitvik GA, Gilje B, Gravdehaug B, Heie A, Janssen E, Kiserud CE, Kursetgjerde T, Langerød A, Lømo J, Mannsåker B, Mortensen E, Olsson P, Porojnicu AC, Raj SX, Roe OD, Russnes HEG, Skjerven HK, Songe-Møller S et al. (2025) Cost-effectiveness of Prosigna for Adjuvant Treatment Decisions in Early Breast Cancer: Healthcare Sector and Societal Perspectives Clin Breast Cancer (in press) DOI 10.1016/j.clbc.2025.04.011, PubMed 40348620 Fjørtoft MO, Garred Ø, Lingjærde OC, Lande KT, Ottestad L, Bergheim IR, OSBREAC, Lømo J, LaMont C, Myklebust JH, Russnes H, Huse K, Rye IH (2025) Single-cell analysis reveals tumour size as a key driver of immune cell profile alterations in primary breast tumours and corresponding lymph nodes BJC Rep, 3 (1), 35 DOI 10.1038/s44276-025-00152-3, PubMed 40394379 Røssevold AH, Tekpli X, Lingjærde OC, Russnes HG, Vallon-Christersson J, Borgen E, Lømo J, Garred Ø, Dorraji E, Kristensen VN, Naume B, Kyte JA (2025) High tumor expression of CTLA4 identifies lymph node-negative basal-like breast cancer patients with excellent prognosis Commun Med (Lond), 5 (1), 234 DOI 10.1038/s43856-025-00865-z, PubMed 40523912
